Strengthening commercial and R&D in the US

Novartis is transforming into a ‘pure-play’ Innovative Medicines company.

In a recent Meet Novartis Management Investor Relations session, Rod Wooten, Head of Global Product Strategy & Capabilities at Novartis outlines how strengthening our commercial and R&D interplays in the US is a critical component of our strategic focus and long-term performance.

Our refreshed strategy and the role of the US in strengthening our commercial and R&D approach is summarized in this short extract.

Meet Novartis Management
Event Date: September 22, 2022
Investors Page: bit.ly/3HjdDWX
Link to Novartis Strategy: bit.ly/3iP8cpp

Disclaimer: Meet Novartis Management event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3HiI7IO

Follow @Novartis on Twitter: twitter.com/Novartis
Follow Novartis on LinkedIn: www.linkedin.com/company/novartis